Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy
نویسندگان
چکیده
منابع مشابه
Chemotherapy for breast cancer during pregnancy: is epirubicin safe?
The co-occurrence of cancer and pregnancy is becoming more frequent, given the trend for women to postpone childbearing [1]. As a consequence, the collection of more information about the effects of anticancer agents during pregnancy is useful to improve the existing guidelines. The most frequent solid tumour observed in pregnant women is breast cancer [1]. Among the drugs potentially active in...
متن کاملAdjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets...
متن کاملPharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
AIMS To investigate the pharmacokinetics and pharmacodynamics of epirubicin and paclitaxel in combination, as well as the effects of paclitaxel and its vehicle Cremophor EL on epirubicin metabolism. METHODS Twenty-seven female patients with metastatic breast cancer received epirubicin 90 mg m-2 i.v. followed 15 min or 30 h later by a 3 h i.v. infusion of paclitaxel 175, 200 and 225 mg m-2. Pl...
متن کاملChemotherapy for advanced endometrial cancer with carboplatin and epirubicin.
UNLABELLED Endometrial cancer is the most common gynecological cancer in the Western world. In early-stage disease, surgery remains the mainstay of treatment. Adjuvant pelvic radiotherapy reduces the risk of pelvic recurrence, however, without improvement in overall survival. The aim of the present study was to assess the efficacy and toxicity of carboplatin and epirubicin combination chemother...
متن کاملThe Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
BACKGROUND Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2006
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.22227